The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Service coverage for major depressive disorder: estimated rates of minimally adequate treatment for 204 countries and territories in 2021
Open accessAbstract
BACKGROUND: Access to effective treatment for major depressive disorder remains limited and difficult to track across place and time. We analysed the available data on minimally adequate treatment (MAT) for major depressive disorder globally with the aim of providing a useful metric against which to monitor national responses to the growing public health burden imposed by major depressive disorder. METHODS: MAT was defined as pharmacotherapy (1 month of medication, plus four visits to a medical doctor) or psychotherapy (eight visits with any professional). From existing reviews, we identified mental health surveys that assessed major depressive disorder within the general population as well as health service uptake by individuals with major depressive disorder. Data by ethnicity were not available. Estimates of MAT, antidepressant use, or use of any mental health service were extracted. The latter two estimates were adjusted to reflect likely MAT rates via a network meta-analysis. Adjusted MAT estimates were analysed via a Bayesian meta-regression using the Disease Modelling Meta-Regression (DisMod-MR 2.1) tool. This analysis estimated MAT coverage among people with major depressive disorder by age, sex, location, and year. Final MAT estimates were standardised by age and sex against the existing age and sex distribution of people with major depressive disorder globally. People with lived experience were involved in the design, preparation, interpretation, and writing of this manuscript. FINDINGS: The analysed dataset included 145 estimates from 32 studies, covering 31 countries, 14 regions, and six super-regions. The proportion of people with major depressive disorder receiving MAT globally in 2021 was 9·1% (95% uncertainty interval 7·2-11·6), with 10·2% (8·2-13·1) of females and 7·2% (5·7-9·3) of males with major depressive disorder receiving MAT. MAT coverage was highest in high-income locations (27·0% [21·7-34·4]), with Australasia having the highest rate (29·2% [21·4-40·8]). MAT coverage was lowest in sub-Saharan Africa (2·0% [1·5-2·6]), within which western sub-Saharan Africa (1·8% [1·4-2·5]) had the lowest coverage. Seven countries (Australia, Belgium, Canada, Germany, the Netherlands, South Korea, and Sweden) were estimated to have MAT coverage exceeding 30%, while 90 countries were estimated to have coverage lower than 5%. INTERPRETATION: Despite many gaps in the available data, estimates show that, globally, most individuals with major depressive disorder do not receive MAT. Services must improve to reach a global coverage that better meets the mental health needs of those with major depressive disorder. Urgent attention should be given to the scale-up of effective intervention strategies, especially in low-income and middle-income countries, as well as further research into better quality treatment options for major depressive disorder. We present a means by which the MAT gap for major depressive disorder can be quantified, to monitor and inform action by governments and international partners. FUNDING: Queensland Health and the Bill & Melinda Gates Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In a previous analysis, we estimated that only 9•1% (7•2-11•6) of individuals with major depressive disorder globally in 2021 received minimally adequate treatment.”
From Updated trends in the global prevalence and burden of mental disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 (2026) · cites this paper as [35]
The cited source says what the claim attributes to it.
In the citing paper
“Of the 204 countries and territories included in GBD, only seven (Australia, Belgium, Canada, Germany, the Netherlands, South Korea, and Sweden) reached minimally adequate treatment rates surpassing 30%, and 90 countries had coverage lower than 5%.35”
From Updated trends in the global prevalence and burden of mental disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 (2026) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Santomauro, D. F., Mantilla Herrera, A. M., Shadid, J., Zheng, P., Ashbaugh, C., Pigott, D. M., Abbafati, C., Adolph, C., Amlag, J. O., Aravkin, A. Y., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02143-7 · Cited by 5,444
Self-citationFerrari, A. J., Santomauro, D. F., Aali, A., Abate, Y. H., Abbafati, C., Abbastabar, H., Abd ElHafeez, S., Abdelmasseh, M., Abd-Elsalam, S., Abdollahi, A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00757-8 · Cited by 5,112
Self-citationThe Lancet Commission on global mental health and sustainable development
Patel, V., Saxena, S., Lund, C., Thornicroft, G., Baingana, F., Bolton, P., Chisholm, D., Collins, P. Y., Cooper, J. L., Eaton, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31612-x · Cited by 3,692
Self-citationWang, P. S., Aguilar-Gaxiola, S., Alonso, J., Angermeyer, M. C., Borges, G., Bromet, E. J., Bruffaerts, R., de Girolamo, G., de Graaf, R., Gureje, O., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61414-7 · Cited by 1,655 · cited 1×
“The majority of included studies adhered to the definition of MAT presented by Wang and colleagues 5 derived from evidence-based guidelines 6–8, 12 recommending either pharmacotherapy”
Scaling-up treatment of depression and anxiety: a global return on investment analysis
Chisholm, D., Sweeny, K., Sheehan, P., Rasmussen, B., Smit, F., Cuijpers, P., & Saxena, S. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30024-4 · Cited by 1,451 · cited 1×
“21 Similar analyses investigating lifelong impacts of addressing anxiety, depression, bipolar disorder, and suicide in young people aged 10–19 years across 36 countries estimated a return of US$24 in health and economic benefits to the economy over 80 years, for each $1 spent on the required…”
Self-citationBarriers to mental health treatment: results from the WHO World Mental Health surveys
Andrade, L. H., Alonso, J., Mneimneh, Z., Wells, J. E., Al-Hamzawi, A., Borges, G., Bromet, E., Bruffaerts, R., de Girolamo, G., de Graaf, R., et al. (2014) · Psychological Medicine · doi:10.1017/s0033291713001943 · Cited by 1,289 · cited 2×
“2,10 WHO’s Comprehensive Mental Health Action Plan 2013–30 includes a target that service coverage for depression be increased by at least 50% by 2030 .”
Fullman, N., Yearwood, J., Abay, S. M., Abbafati, C., Abd-Allah, F., Abdela, J., Abdelalim, A., Abebe, Z., Abebo, T. A., Aboyans, V., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30994-2 · Cited by 1,013
Self-citationLehman, A. F., Steinwachs, D. M., & The Co-Investigators of the PORT Project (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033302 · Cited by 910
Scale up services for mental disorders: a call for action
(2007) · The Lancet · doi:10.1016/s0140-6736(07)61242-2 · Cited by 835
Cited by
Santomauro, D. F., Miller, P. A., Shadid, J., Wulf Hanson, S., Vo, A., Roy, D. J., Hagins, H., Mantilla Herrera, A. M., Scott, J. G., Erskine, H. E., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00519-2 · Cited by 83
Self-citation
Metadata
- Authors
- Santomauro, D. F., Vos, T., Whiteford, H. A., Chisholm, D., Saxena, S., & Ferrari, A. J.
- Affiliations
- The University of Queensland (AU)
- University of Washington (US)
- World Health Organization (CH)
- Harvard University (US)
- Corresponding author
- Santomauro, Damian F
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2024-12
- Volume
- 11
- Issue
- 12
- Pages
- 1012-1021
- ISSN
- 2215-0366 (ISSN-L)
- PMC
- PMC11579305
- OpenAlex
- W4404514335
- Cited by
- 57
- References
- 22
- Citations by year
- 2026: 39 · 2025: 17 · 2024: 1
- FWCI
- 26.95
- Type
- journal article
- Language
- en
- Update notices
- erratum (2025-01-01)
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/3.0/igo/ (vor)
- Locations
- The Lancet Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Bill & Melinda Gates Foundation
- Queensland Health
- Queensland Government
- Tasmanian Department of Health
- World Health Organization
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Applied Psychology › Digital Mental Health Interventions
- Keywords
- major depressive disorder, treatment coverage, antidepressant use, psychotherapy, mental health service utilization, global mental health, sub-Saharan Africa, sex differences in treatment, high-income countries, low-income countries, Bayesian meta-regression, lived experience of mental illness, mental health professionals, mental health funding
- MeSH terms
- Adolescent, Adult, Aged, Antidepressive Agents, Bayes Theorem, Major Depressive Disorder, Female, Health Services Accessibility, Humans, Male, Mental Health Services, Middle Aged, Psychotherapy, Global Health, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Service coverage for major depressive disorder: estimated rates of minimally adequate treatment for 204 countries and territories in 2021. https://app.cochat.ai/papers/10.1016/s2215-0366(24)00317-1
- The paper
- Santomauro, D. F., Vos, T., Whiteford, H. A., Chisholm, D., Saxena, S., & Ferrari, A. J. (2024). Service coverage for major depressive disorder: estimated rates of minimally adequate treatment for 204 countries and territories in 2021. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(24)00317-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.